ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements with these filters
Aarey Drugs & Pharmaceuticals Ltd filed its quarterly shareholding pattern. This is a routine regulatory compliance disclosure regarding the company's equity distribution.
Aarey Drugs approved the Board Report and called its 36th Annual General Meeting to be held on September 30, 2026.
Aarey Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹44.6 Cr (-56.4% YoY) and net profit of ₹1 Cr (-28.6% YoY) for Q1 FY27.
Aarey Drugs & Pharmaceuticals will hold a board meeting on August 14, 2026, to consider and approve the standalone unaudited financial results for the June 2026 quarter.
Aarey Drugs allotted 25.20 lakh equity shares upon conversion of warrants, raising Rs. 12.06 Crore. This issuance changes the company's paid-up equity capital.
The company has filed its quarterly shareholding pattern for the period ending June 30, 2026, as per regulatory requirements.
Aarey Drugs & Pharmaceuticals filed its Annual Secretarial Compliance Report for FY 2025-26. The report details regulatory compliance status and observations from the practicing company secretary.
Aarey Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹189.5 Cr (+75.3% YoY) and net profit of ₹1.6 Cr (+220.0% YoY) for Q4 FY26.
Aarey Drugs & Pharmaceuticals approved audited standalone financial results for FY26. The board also recorded a statement of no deviation in the utilization of preferential issue funds.
Aarey Drugs & Pharmaceuticals postponed its May 29 board meeting to May 30, 2026. The meeting will consider audited FY2026 financial results.
Aarey Drugs & Pharmaceuticals scheduled a board meeting on May 29, 2026, to approve audited annual financial results. The trading window remains closed for designated persons.
Aarey Drugs clarified a clerical mismatch in previously reported Profit After Tax figures. The company has re-uploaded revised integrated financial results to ensure regulatory consistency.